Ozempic, a GLP-1 receptor agonist for type-2 diabetes, was launched in India on Dec 12 Doctors warn Ozempic is not a cosmetic weight-loss drug and requires medical supervision Potential side effects include dehydration, pancreatitis, and risks with thyroid history
